GYRE
GYRE THERAPEUTICS, INC.
Key Financials
Net Income
$9.9M
↓ 44.8%
Gross Profit
$101.9M
↓ 6.4%
Operating Income
$11.5M
↓ 28.9%
Revenue
$116.6M
↑ 10.2%
EPS (Diluted)
$0.02
↓ 60.0%
Total Liabilities
$23.9M
↓ 11.7%
Cash & Equivalents
$37.1M
↑ 213.8%
Total Assets
$166.1M
↑ 32.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GYRE |
| Company Name | GYRE THERAPEUTICS, INC. |
| CIK | 1124105 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 567-7770 |